Henan Taloph Pharmaceutical Stock (600222.SH): has repurchased a total of 1.04% of its shares.
Gelonghui reported on January 13 that Henan Taloph Pharmaceutical Stock (600222.SH) announced that as of January 13, 2025, the company has cumulatively repurchased 5,947,100 shares through centralized bidding trade, accounting for 1.04% of the company's total share capital, an increase of 0.22% compared to the last disclosed number. The highest price for the repurchased shares was 5.42 yuan/share, the lowest price was 3.82 yuan/share, and the total amount paid was 27,547,437.40 yuan (excluding trading fees).
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Henan Taloph Pharmaceutical Stock (600222.SH): Participating in the national Chinese Patent Medicine procurement alliance's centralized volume procurement is expected to be selected.
On January 2, Gelonghui reported that Henan Taloph Pharmaceutical Stock (600222.SH) announced its participation in the national centralized procurement bidding organized by the National Chinese Patent Medicine Joint Procurement Office (referred to as "Joint Procurement Office"). According to the announcement released by the Joint Procurement Office on December 30, 2024, regarding the planned selection results for the national centralized procurement alliance of Chinese Patent Medicine, the company's products, Shuanghuanglian Oral Liquid and Danshen Oral Liquid, are proposed to be selected for this centralized procurement.
Henan taloph pharmaceutical stock (600222.SH): The proportion of shares indirectly controlled by shanghai land increased to 8.71%.
On December 9, Gelonghui reported that Henan Taloph Pharmaceutical Stock (600222.SH) announced it had received a notice from shareholders Zhongsheng Industrial regarding changes in equity. During this period, its indirect shareholder Shanghai Landu Health Industry Investment Management Co., Ltd. (referred to as "Shanghai Landu") gained control of Zhongsheng Industrial's shareholders Gongyi City Zhulin Jinzhu Trading Co., Ltd. (referred to as "Jinzhu Trading") and Gongyi City Zhulin Litian Technology Development Co., Ltd. (referred to as "Litian Technology") due to an agreement, resulting in an increase in the proportion of shares indirectly controlled by Shanghai Landu in the company from 0% to 8.71%. This change in equity does not trigger a mandatory takeover offer and does not involve the company's control.
henan taloph pharmaceutical stock (600222.SH) plans to distribute 0.1 yuan per 10 shares in the first three quarters, with ex-rights and ex-dividends on December 9.
henan taloph pharmaceutical stock (600222.SH) announced that the company plans to distribute 1 share for every 10 shares to all shareholders in the first three quarters of 2024...
Solid Earnings May Not Tell The Whole Story For Henan Taloph Pharmaceutical StockLtd (SHSE:600222)
Tailong Pharmaceutical Report for the Third Quarter of 2024
Henan Taloph Pharmaceutical Stock (600222.SH): The net income for the first three quarters was 28.8959 million yuan, a year-on-year increase of 270.72%.
On October 24, Gelonhui reported that Henan Taloph Pharmaceutical Stock (600222.SH) released its third quarter report for 2024, with the company's revenue for the first three quarters of the year at 1.341 billion yuan, a 7.08% year-on-year decrease; net income attributable to shareholders of the listed company was 28.8959 million yuan, a 270.72% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.4868 million yuan, a 181.61% year-on-year increase; and the basic earnings per share was 0.0519 yuan.
henan taloph pharmaceutical stock (600222.SH): Currently, products such as Huoxiang Zhengqi Formula, Wuzi Yanzong Oral Liquid, and Shengmai Yin have all been successfully launched for production.
On October 8th, Henan Taloph Pharmaceutical Stock (600222.SH) stated in a recent performance briefing that the company adheres to the operation philosophy of being an expert in traditional chinese medicine oral liquids, market-driven, and in recent years has continuously increased the production of chinese patent medicine products through product introduction, research on classic formulas, and development of drugs with the same name and formula, promoting the diversified development of products and constructing a scientific product portfolio. Currently, products introduced such as the Huoxiang Zhengqi mixture, Wuzi Yanzong oral liquid, Shengmai Yin, have all been successfully launched for production.
There's No Escaping Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) Muted Revenues
Henan Taloph Pharmaceutical Stock (600222.SH): The company did not implement share repurchase in August.
As of August 2024, Henan Taloph Pharmaceutical Stock (600222.SH) announced that the company did not implement any share repurchases. As of August 31, 2024, the company has repurchased a total of 4,693,600 shares, accounting for 0.82% of the total share capital of the company. The highest price of the repurchase transaction was 4.97 yuan/share, and the lowest price was 3.82 yuan/share. The total amount paid was 21,274,189.00 yuan (excluding transaction costs). The repurchase of the shares mentioned above complies with the relevant laws and regulations and the requirements of the company's share repurchase program.
Henan Taloph Pharmaceutical (600222.SH): Received a government subsidy of RMB 3.5223 million.
Gelonghui August 30th | Henan Taloph Pharmaceutical Stock (600222.SH) announced that the company and its subsidiaries received a total of 3.5223 million yuan in government subsidies from January 1, 2024 to August 30, 2024, all of which are government subsidies related to income, accounting for 8.09% of the net income attributable to the shareholders of the listed company as audited in the most recent period.
Henan Taloph Pharmaceutical Stock 2024 Interim Report
太龙药业2024年半年度报告摘要
Henan Taloph Pharmaceutical Stock (600222.SH): The net income in the first half of the year was 26.618 million yuan, turning losses into profits year-on-year.
On August 21st, Taloph Pharmaceutical (600222.SH) released its semi-annual report for 2024. During the reporting period, the company achieved a revenue of 0.927 billion yuan, a year-on-year decrease of 6.71%; the net income attributable to shareholders of the listed company was 26.618 million yuan, turning losses into profits year-on-year; the basic earnings per share were 0.0477 yuan. During the reporting period, the net income attributable to the parent company increased by 64.9498 million yuan compared to the same period last year. Excluding the temporary increase in demand for heat-clearing and detoxifying drugs at the beginning of the previous year, which affected the pharmaceutical formulation business, the company's main business sectors have maintained a growth trend. By continuously optimizing the product portfolio and customer structure, the company has strengthened lean management.
Henan Taloph Pharmaceutical Stock (600222.SH): No vitamin-related products currently available.
Henan Taloph Pharmaceutical Stock (600222.SH) stated on the investor communication platform that the company currently does not have any products related to vitamins.
While Shareholders of Henan Taloph Pharmaceutical StockLtd (SHSE:600222) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown
Henan Taloph Pharmaceutical Stock's performance pre-announcement for the first half of 2024.
Henan Taloph Pharmaceutical Stock (600222.SH) will distribute 0.018 yuan per share for the first quarter of 2024. The equity record date is July 8.
Henan Taloph Pharmaceutical Stock (600222.SH) released a notice on the implementation of equity distribution for the first quarter of 2024. The profit distribution for this time...
Henan Taloph Pharmaceutical Stock (600222.SH): Has repurchased 0.82% of its shares.
On July 2nd, Gelunhui reported that Henan Taloph Pharmaceutical Stock (600222.SH) has repurchased a total of 4,693,600 shares as of June 30, 2024, accounting for 0.82% of the total share capital. The highest repurchase price was 4.97 yuan per share, the lowest was 3.82 yuan per share, and the total amount paid was 21,274,189.00 yuan (excluding transaction fees).